Table 3.
Univariate and multivariate Cox regression analysis for predicting the primary endpoint
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| GRACE score | 1.0253 | 1.0182 to 1.0325 | < 0.0001 | 1.0202 | 1.0117 to 1.0288 | < 0.0001 |
| Female | 1.5832 | 1.0334 to 2.4255 | 0.0348 | 1.3103 | 0.8403 to 2.0431 | 0.2332 |
| BMI | 0.9528 | 0.8841 to 1.0268 | 0.2050 | |||
| Smoking | 0.7895 | 0.5222 to 1.1936 | 0.2623 | |||
| Previous PCI | 1.3968 | 0.7428 to 2.6268 | 0.2997 | |||
| Hypertension | 1.3202 | 0.8409 to 2.0728 | 0.2274 | |||
| Diabetes mellitus | 1.2838 | 0.8433 to 1.9544 | 0.2440 | |||
| TyG index | 1.4961 | 1.1437 to 1.9571 | 0.0033 | 1.6028 | 1.1900 to 2.1588 | 0.0019 |
| HDL-C | 0.9716 | 0.4767 to 1.9805 | 0.9368 | |||
| LDL-C | 0.9249 | 0.7572 to 1.1297 | 0.4441 | |||
| bSS | 1.0537 | 1.0324 to 1.0755 | < 0.0001 | 1.0244 | 0.9992 to 1.0502 | 0.0574 |
| ICR | 1.9863 | 1.2077 to 3.2669 | 0.0069 | 1.2399 | 0.7231 to 2.1259 | 0.4345 |
| LVEF | 0.9448 | 0.9269 to 0.9629 | < 0.0001 | 0.9773 | 0.9548 to 1.0003 | 0.0530 |
| AMI | 1.9438 | 1.2533 to 3.0148 | 0.0030 | 0.8695 | 0.5326 to 1.4196 | 0.5761 |
| β-blockers | 0.9299 | 0.5975 to 1.4473 | 0.7475 | |||
| Diuretics | 3.2982 | 2.1419 to 5.0787 | < 0.0001 | 1.5413 | 0.9234 to 2.5727 | 0.0979 |
| ACEI/ARB | 1.2600 | 0.8330 to 1.9057 | 0.2737 | |||
| Insulin | 1.4863 | 0.7696 to 2.8704 | 0.2380 | |||
The primary endpoint was defined as a composite of all-cause death and nonfatal myocardial infarction. HR, hazard ratio; CI, confidence interval; GRACE score, Global Registry of Acute Coronary Events score; the TyG index, the triglyceride-glucose index; BMI, body mass index; FBG, fasting blood glucose; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein; CTO, chronic total occlusion; ICR, incomplete revascularization; LVEF, left ventricular ejection fraction; AMI, acute myocardial infarction; bSS, baseline SYNTAX score; rSS, residual SYNTAX score; ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker